Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 4. Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on the stock and has a $196.00 price target.
Michael Ulz has given his Buy rating due to a combination of factors surrounding Sarepta Therapeutics’ recent developments. The independent data monitoring committee (IDMC) has evaluated the benefit-risk profile of Sarepta’s Elevidys trials and concluded that it remains favorable. This conclusion supports the continuation of the trials without any amendments, which is a positive indicator for the company’s prospects.
Additionally, Sarepta’s proactive approach in addressing the temporary clinical hold imposed by the EMA, following a patient incident, demonstrates their commitment to resolving regulatory concerns swiftly. The company’s expectation of minimal impact on the study timelines further contributes to the positive outlook, reinforcing the Buy rating as Sarepta navigates through these challenges effectively.
Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Viking Therapeutics. According to TipRanks, Ulz has an average return of -9.1% and a 33.91% success rate on recommended stocks.
In another report released on April 4, Barclays also reiterated a Buy rating on the stock with a $209.00 price target.